Autoimmune hepatitis - update on clinical management in 2017

Timur Liwinski; Christoph Schramm

doi:10.1016/j.clinre.2017.07.002

Autoimmune hepatitis - update on clinical management in 2017

Standard

Autoimmune hepatitis - update on clinical management in 2017. / Liwinski, Timur; Schramm, Christoph.

in: CLIN RES HEPATOL GAS, Jahrgang 41, Nr. 6, 12.2017, S. 617-625.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Review › Forschung

Harvard

Liwinski, T & Schramm, C 2017, 'Autoimmune hepatitis - update on clinical management in 2017', CLIN RES HEPATOL GAS, Jg. 41, Nr. 6, S. 617-625. https://doi.org/10.1016/j.clinre.2017.07.002

APA

Liwinski, T., & Schramm, C. (2017). Autoimmune hepatitis - update on clinical management in 2017. CLIN RES HEPATOL GAS, 41(6), 617-625. https://doi.org/10.1016/j.clinre.2017.07.002

Vancouver

Liwinski T, Schramm C. Autoimmune hepatitis - update on clinical management in 2017. CLIN RES HEPATOL GAS. 2017 Dez;41(6):617-625. https://doi.org/10.1016/j.clinre.2017.07.002

Bibtex

@article{49b5bf908dce4a7ebcd80584dcdc7790,

title = "Autoimmune hepatitis - update on clinical management in 2017",

abstract = "Autoimmune hepatitis (AIH) is a progressive immune mediated liver disease of unknown origin. Key diagnostic features include hypergammaglobulinemia/elevated serum-IgG, characteristic circulating autoantibodies, periportal hepatitis with interface activity on liver biopsy and the exclusion of hepatotropic viruses. However, the diagnosis is challenging in cholestatic and severe presentations. It can be difficult to differentiate AIH from drug-induced liver injury. Although many patients initially respond to standard immunosuppressive therapy, a significant proportion experiences intolerable side effects or insufficient treatment response. This underlines the need for effective alternative treatment options, which are still very limited and based on rather poor evidence. This review summarises core aspects of the clinical management of AIH with focus on recent achievements and unmet needs.",

keywords = "Journal Article, Review",

author = "Timur Liwinski and Christoph Schramm",

year = "2017",

month = dec,

doi = "10.1016/j.clinre.2017.07.002",

language = "English",

volume = "41",

pages = "617--625",

journal = "CLIN RES HEPATOL GAS",

issn = "2210-7401",

publisher = "Elsevier Masson",

number = "6",

}

RIS

TY - JOUR

T1 - Autoimmune hepatitis - update on clinical management in 2017

AU - Liwinski, Timur

AU - Schramm, Christoph

PY - 2017/12

Y1 - 2017/12

N2 - Autoimmune hepatitis (AIH) is a progressive immune mediated liver disease of unknown origin. Key diagnostic features include hypergammaglobulinemia/elevated serum-IgG, characteristic circulating autoantibodies, periportal hepatitis with interface activity on liver biopsy and the exclusion of hepatotropic viruses. However, the diagnosis is challenging in cholestatic and severe presentations. It can be difficult to differentiate AIH from drug-induced liver injury. Although many patients initially respond to standard immunosuppressive therapy, a significant proportion experiences intolerable side effects or insufficient treatment response. This underlines the need for effective alternative treatment options, which are still very limited and based on rather poor evidence. This review summarises core aspects of the clinical management of AIH with focus on recent achievements and unmet needs.

AB - Autoimmune hepatitis (AIH) is a progressive immune mediated liver disease of unknown origin. Key diagnostic features include hypergammaglobulinemia/elevated serum-IgG, characteristic circulating autoantibodies, periportal hepatitis with interface activity on liver biopsy and the exclusion of hepatotropic viruses. However, the diagnosis is challenging in cholestatic and severe presentations. It can be difficult to differentiate AIH from drug-induced liver injury. Although many patients initially respond to standard immunosuppressive therapy, a significant proportion experiences intolerable side effects or insufficient treatment response. This underlines the need for effective alternative treatment options, which are still very limited and based on rather poor evidence. This review summarises core aspects of the clinical management of AIH with focus on recent achievements and unmet needs.

KW - Journal Article

KW - Review

U2 - 10.1016/j.clinre.2017.07.002

DO - 10.1016/j.clinre.2017.07.002

M3 - SCORING: Review article

C2 - 28882739

VL - 41

SP - 617

EP - 625

JO - CLIN RES HEPATOL GAS

JF - CLIN RES HEPATOL GAS

SN - 2210-7401

IS - 6

ER -